Lexington, MA – According to filings with the U.S. Securities and Exchange Commission, Fractyl Laboratories is raising $44,750,503.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Harith Rajagopalan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Fractyl Laboratories

At Fractyl, we are applying new scientific insights in intestinal biology to advance treatments and potential cures for metabolic diseases. Our growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. We are currently advancing global clinical development of Revita DMR, initially targeting patients with conditions resulting from insulin resistance, including type 2 diabetes (T2D), nonalcoholic steatohepatitis (NASH), and polycystic ovarian syndrome (PCOS), while also exploring use of Revita DMR in combination with cell and gene therapy.

To learn more about Fractyl Laboratories, visit http://fractyl.com/

Contact:
Harith Rajagopalan, President and Chief Executive Officer
781-902-8800
harith@fractyl.com
https://www.linkedin.com/in/harith-rajagopalan-fractyl/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved